EBV-Associated Lymphoproliferative Disorders: Update in Classification

Surg Pathol Clin. 2019 Sep;12(3):745-770. doi: 10.1016/j.path.2019.03.002.

Abstract

Although about 90% of the world's population is infected by EBV only a small subset of the related infections result in neoplastic transformation. EBV is a versatile oncogenic agent involved in a multitude of hematopoietic, epithelial, and mesenchymal neoplasms, but the precise role of EBV in the pathogenesis of many of the associated lymphoid/histiocytic proliferations remains hypothetical or not completely understood. Additional studies and use of evolving technologies such as high-throughput next-generation sequencing may help address this knowledge gap and may lead to enhanced diagnostic assessment and the development of potential therapeutic interventions.

Keywords: B-cell lymphoproliferative disorders; EBV; Immunodeficiency-related lymphoproliferative disorders; T-cell lymphoproliferative disorders.

Publication types

  • Review

MeSH terms

  • Animals
  • Chronic Disease
  • Culicidae
  • Diagnosis, Differential
  • Epstein-Barr Virus Infections / classification*
  • Humans
  • Hydroa Vacciniforme / diagnosis
  • Immunosuppressive Agents / adverse effects
  • Infectious Mononucleosis / diagnosis
  • Insect Bites and Stings / diagnosis
  • Lymphoma, B-Cell / classification
  • Lymphoma, B-Cell / virology
  • Lymphoma, T-Cell / classification
  • Lymphoma, T-Cell / virology
  • Lymphomatoid Granulomatosis / diagnosis
  • Lymphoproliferative Disorders / classification*
  • Lymphoproliferative Disorders / virology
  • Neoplasms, Plasma Cell / diagnosis
  • Prognosis
  • Pseudolymphoma / diagnosis
  • Pseudolymphoma / virology
  • Virus Latency / physiology

Substances

  • Immunosuppressive Agents